Satsuma pulped as acute migraine drug flunks phase 3 trial

Shares in California biotech Satsuma Pharma have lost three quarters of their value after lead drug STS01 failed to show any improvement over placebo in an acute migraine study.

Lilly announces CNS tie-up with UK biotech Evox Therapeutics

Eli Lilly has announced a central nervous system research tie-up with UK biotech Evox Therapeutics, which focuses on drug engineering using vesicles to deliver drugs to targets. 

Novartis builds case for MS drug ofatumumab as FDA decision ...

Novartis has reported new data with its multiple sclerosis (MS) drug ofatumumab showing that it can suppress disease activity for up to two years, as it waits for an FDA decisi

Failed trial puts future of UCB’s epilepsy drug padsevonil i...

France’s MedDay says drug for MS falls at phase 3 hurdle

Blockbusters in waiting: drug launches to watch in 2020